Modified vaccinia ankara
Identification
- Summary
Modified vaccinia ankara is a live, non-replicating orthopoxvirus vaccine used to prevent smallpox, monkeypox, and other diseases caused by vaccinia virus.
- Brand Names
- Jynneos
- Generic Name
- Modified vaccinia ankara
- DrugBank Accession Number
- DB15483
- Background
Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).2,3
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Modified Vaccinia Virus (Ankara-Bavarian Nordic)
- MVA
- MVA-BN
- Vaccinia strain modified ankara
Pharmacology
- Indication
Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.1 In the EU, it is additionally indicated for the prevention of other diseases caused by the vaccinia virus.3
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
Vaccination with Modified Vaccinia Ankara elicits humoral and cellular immune responses to orthopoxviruses, thereby providing host protection against future orthopoxvirus infections.1
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Anakinra. Anifrolumab The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Anifrolumab. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Imvamune Suspension 50000000 CCID50 / 0.5 mL Subcutaneous Bavarian Nordic As 2015-06-15 Not applicable Canada Imvanex Injection, suspension 50000000 Inf. U Subcutaneous Bavarian Nordic A/S 2020-12-18 Not applicable EU Jynneos Injection, suspension 50000000 1/0.5mL Subcutaneous Bavarian Nordic A/S 2021-03-17 Not applicable US Mvabea Injection, suspension 70000000 Inf. U Intramuscular Janssen Cilag International Nv 2021-02-11 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- TU8J357395
- CAS number
- Not Available
References
- General References
- DailyMed Label: JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating) suspension for subcutaneous injection [Link]
- FDA Approved Drug Products: Jynneos (smallpox and monkeypox vaccine, live, non-replicating) for suspension for subcutaneous injection [Link]
- EMA Summary of Product Characteristics: Imvanex (Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)) for subcutaneous injection [Link]
- Health Canada Product Monograph: IMVAMUNE (modified vaccinia ankara) injection [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Vaccinations 1 3 Active Not Recruiting Prevention Ebolavirus Disease 1 3 Active Not Recruiting Prevention Infections, Respiratory Syncytial Virus 1 3 Active Not Recruiting Prevention Monkeypox Virus Infection 1 3 Completed Prevention 18-42 Year Old Healthy Vaccinia-naïve Subjects 1 3 Completed Prevention Ebola 1 3 Completed Prevention Healthy Subjects (HS) 2 3 Completed Prevention Hemorrhagic Fever, Ebola 1 3 Completed Prevention Variola Major (Smallpox) 2 2 Active Not Recruiting Prevention Monkeypox 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Subcutaneous 50000000 CCID50 / 0.5 mL Injection, suspension Subcutaneous 50000000 U.inf. Injection, suspension Subcutaneous 50000000 Inf. U Injection, suspension Subcutaneous 50000000 1/0.5mL Injection, suspension Intramuscular 0.5 ML Injection, suspension Intramuscular 70000000 Inf. U - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at August 30, 2019 17:59 / Updated at December 01, 2022 11:29